Retinal Perforation

Categories: Eye diseases

Aliases & Classifications for Retinal Perforation

MalaCards integrated aliases for Retinal Perforation:

Name: Retinal Perforation 12 15
Retinal Perforations 44 73
Retinal Dialysis 12
Retinal Break 12
Retinal Tear 12


External Ids:

Disease Ontology 12 DOID:12514
MeSH 44 D012167
NCIt 50 C50732
ICD10 33 H33.3
UMLS 73 C0035321

Summaries for Retinal Perforation

MalaCards based summary : Retinal Perforation, also known as retinal perforations, is related to retinal detachment and strabismus. An important gene associated with Retinal Perforation is PAX6 (Paired Box 6), and among its related pathways/superpathways are Degradation of the extracellular matrix and Collagen chain trimerization. The drugs Bevacizumab and Angiogenesis Inhibitors have been mentioned in the context of this disorder. Affiliated tissues include eye, and related phenotypes are growth/size/body region and craniofacial

Related Diseases for Retinal Perforation

Graphical network of the top 20 diseases related to Retinal Perforation:

Diseases related to Retinal Perforation

Symptoms & Phenotypes for Retinal Perforation

MGI Mouse Phenotypes related to Retinal Perforation:

# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 9.73 COL2A1 ESCO2 KCNJ13 P3H1 PAX6 COL11A1
2 craniofacial MP:0005382 9.67 COL2A1 KCNJ13 PAX6 COL11A1
3 digestive/alimentary MP:0005381 9.62 COL2A1 KCNJ13 PAX6 COL11A1
4 hearing/vestibular/ear MP:0005377 9.46 P3H1 PAX6 COL11A1 COL2A1
5 respiratory system MP:0005388 9.26 COL2A1 KCNJ13 PAX6 COL11A1
6 skeleton MP:0005390 9.02 KCNJ13 P3H1 PAX6 COL11A1 COL2A1

Drugs & Therapeutics for Retinal Perforation

Drugs for Retinal Perforation (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 77)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Bevacizumab Approved, Investigational Phase 4,Not Applicable 216974-75-3
2 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
3 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
Ranibizumab Approved Phase 3,Phase 2,Phase 1 347396-82-1 459903
Sulfamethazine Approved, Investigational, Vet_approved Phase 3 57-68-1 5327
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
Povidone-iodine Approved Phase 3 25655-41-8
Triamcinolone Approved, Vet_approved Phase 3,Phase 1,Phase 2 124-94-7 31307
Lutein Approved, Investigational, Nutraceutical Phase 3 127-40-2 6433159
10 Fibrinolytic Agents Phase 3,Phase 2,Phase 1
11 Plasminogen Phase 3,Phase 2,Phase 1
12 Anesthetics Phase 3,Not Applicable
13 Antiemetics Phase 3,Not Applicable
14 Anti-Infective Agents Phase 3,Not Applicable
15 Anti-Inflammatory Agents Phase 3,Phase 2,Phase 1,Not Applicable
16 Antineoplastic Agents, Hormonal Phase 3,Not Applicable
17 Autonomic Agents Phase 3,Not Applicable
18 BB 1101 Phase 3
19 Dexamethasone acetate Phase 3 1177-87-3
20 Gastrointestinal Agents Phase 3,Not Applicable
21 glucocorticoids Phase 3,Phase 1,Phase 2,Not Applicable
22 HIV Protease Inhibitors Phase 3
23 Hormone Antagonists Phase 3,Phase 1,Phase 2,Not Applicable
24 Hormones Phase 3,Phase 1,Phase 2,Not Applicable
25 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 1,Phase 2,Not Applicable
26 Immunosuppressive Agents Phase 3,Phase 1,Phase 2
27 Peripheral Nervous System Agents Phase 3,Phase 2,Not Applicable
protease inhibitors Phase 3
29 triamcinolone acetonide Phase 3,Phase 1,Phase 2
30 Triamcinolone diacetate Phase 3,Phase 1,Phase 2
31 Triamcinolone hexacetonide Phase 3,Phase 1,Phase 2
Bromfenac Approved July 1997 Phase 2 91714-94-2 60726
Fibrinolysin Investigational Phase 2 9004-09-5
34 Analgesics Phase 2
35 Analgesics, Non-Narcotic Phase 2
36 Anti-Inflammatory Agents, Non-Steroidal Phase 2
37 Antirheumatic Agents Phase 2
38 Ophthalmic Solutions Phase 2,Not Applicable
39 Pharmaceutical Solutions Phase 2,Not Applicable
40 Tetrahydrozoline Phase 2,Not Applicable
41 Mitogens Phase 2
42 Tissue Plasminogen Activator Phase 1
Temazepam Approved, Investigational Not Applicable 846-50-4 5391
Methylprednisolone Approved, Vet_approved Not Applicable 83-43-2 6741
Prednisolone Approved, Vet_approved Not Applicable 50-24-8 5755
Benzocaine Approved, Investigational Not Applicable 1994-09-7, 94-09-7 2337
Dipivefrin Approved Not Applicable 52365-63-6 3105
Dorzolamide Approved Not Applicable 120279-96-1 3154 5284549
Timolol Approved Not Applicable 26839-75-8 33624 5478
50 tannic acid Approved, Nutraceutical Not Applicable

Interventional clinical trials:

(show top 50) (show all 111)
# Name Status NCT ID Phase Drugs
1 Effects of Different Area of Internal Limiting Membrane Peeling (ILM) Peeling on Anatomical Outcomes in Macular Hole Surgery Completed NCT02930369 Phase 4
2 Prospective Randomized Controlled Study of Intravitreal Injection of Bevacizumab for Proliferative Diabetic Retinopathy Completed NCT01854593 Phase 4 Bevacizumab
3 Study of Surgery in Patients With Idiopathic Macular Hole Recruiting NCT02905409 Phase 4
4 Day Regimes of CONbercept on CytokinEs of PDR Patients Undergoing Vitrectomy - Trial (CONCEPT) Recruiting NCT03506750 Phase 4 IVC
5 Evaluation of Ranibizumab in Proliferative Diabetic Retinopathy (PDR) Requiring Vitrectomy Unknown status NCT00516464 Phase 3 Lucentis (ranibizumab)
6 Safety and Efficacy of Double Staining With Brilliant Blue G for Macular Surgery Unknown status NCT01820520 Phase 3 brilliant blue G
7 Brilliant Blue Versus Indocyanine Green Unknown status NCT01083004 Phase 3
8 Double-dose Ranibizumab for Polypoidal Choroidal Vasculopathy Unknown status NCT02769169 Phase 2, Phase 3 Lucentis® (Raibizumab) double-dose;Lucentis® (Raibizumab) regular-dose
9 Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-006) Trial. Completed NCT00781859 Phase 3 125 µg Ocriplasmin;Placebo
10 Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole Completed NCT01429441 Phase 3 Ocriplasmin
11 Association of Lutein, Zeaxanthin and Brilliant Blue in Chromovitrectomy Completed NCT01627977 Phase 3
12 SUSTAIN - Study of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration Completed NCT00331864 Phase 3 Ranibizumab
13 PeriOcular and INTravitreal Corticosteroids for Uveitic Macular Edema Trial Completed NCT02374060 Phase 3 Periocular triamcinolone 40 mg;Intravitreal triamcinolone 4 mg;Dexamethasone intravitreal implant
14 Safety and Efficacy of Intravitreal Ranibizumab as a Preoperative Adjunct Treatment Before Vitrectomy Surgery in Proliferative Diabetic Retinopathy (PDR) Compared to Vitrectomy Alone Unknown status NCT00931125 Phase 2 ranibizumab and vitrectomy
15 Combination Ranibizumab and Bromfenac for Neovascular Age-related Macular Degeneration Completed NCT00805233 Phase 2 combination ranibizumab + bromfenac;ranibizumab injection alone
16 A Study of the Safety and Efficacy of Microplasmin to Induce a Posterior Vitreous Detachment (MIVI III) Completed NCT00412958 Phase 2 Ocriplasmin 25µg;Ocriplasmin 75µg;Ocriplasmin 125µg;Placebo
17 20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD) Completed NCT01175395 Phase 1, Phase 2 IBI-20089/Lucentis
18 Analysis of Aqueous and Vitreous Humor Recruiting NCT02067013 Phase 2 Ranibizumab
19 Study of Denufosol (INS37217) in Subjects With Rhegmatogenous Retinal Detachment Terminated NCT00083967 Phase 2 denufosol tetrasodium (INS37217) Intravitreal Injection
20 Study of OT-551 Eye Drops to Prevent or Delay Progression of Nuclear Cataracts Following Vitreous Removal Terminated NCT00333060 Phase 2 OT-551 ophthalmic solution
21 Efficacy and Safety Study of CNTO 2476 in Participants With Visual Acuity Impairment Associated With Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD) Withdrawn NCT02895815 Phase 2
22 Partial Posterior Hyaloidectomy in Macular Surgery Completed NCT01454466 Phase 1
23 Ranibizumab in Hemorrhagic Choroidal Neovascularization Trial Completed NCT00363168 Phase 1 Ranibizumab;Ranibizumab
24 Surgical Stabilizer Assisted RVC With rtPA for CRVO Not yet recruiting NCT03417401 Phase 1 Intravenous Infusion
25 Short Term Postoperative Tamponade Using Perfluorocarbon Liquid for Giant Retinal Tears Unknown status NCT01604616
26 Early Vitrectomy for Impending Macular Hole Unknown status NCT01121965 Not Applicable
27 Double Endotamponade With Perfluorodecalin and Silicone Oil in Retinal Detachment Surgery. Unknown status NCT01959568 Not Applicable
28 Macular Hole Surgery With and Without Internal Limiting Membrane Peeling:A Systematic Review and Meta-analysis Unknown status NCT01687829
29 The Intravitreal Autologous Platelet Concentrate Injection as an Adjunct of Vitrectomy for the Treatment of Refractory Macular Holes Unknown status NCT02081170 Not Applicable
30 Inverted ILM Repositioning as Treatment for Full Thickness Macular Holes Unknown status NCT01228188 Not Applicable
31 Comparison of Postoperative Aqueous Flare After 20G Versus 23G Pars Plana Vitrectomy Unknown status NCT01969929 Not Applicable
32 Triple Therapy for Diffuse Diabetic Macular Edema Unknown status NCT01218750 Not Applicable
33 Optical Coherence Tomography - Rescan During Dissection of Macular Membranes Unknown status NCT02748421 Not Applicable
34 Inverted Internal Limiting Membrane Flap Technique for Macular Hole Retinal Detachment in Highly Myopic Eyes Completed NCT02896972 Not Applicable
35 Vitrectomy and Scleral Shortening for Macular Hole Retinal Detachment or Myopic Traction Maculopathy Completed NCT02528045
36 Topical Use of Corticosteroid to Prevent Epiretinal Membrane Following Retinal Tear Completed NCT02412059 Not Applicable Prednisolone acetate
37 Evaluation of a New Surgical Technique for Macular Hole Which Was Not Closed After a Previous Surgery Completed NCT02946372 Not Applicable
38 Scleral Self-indentation Chandelier-assisted Peripheral Vitrectomy Under Air Rhegmatogenous Retinal Detachment. Completed NCT03218371
39 Optical Coherence Tomography in Gas-filled Eyes Completed NCT01266746
40 Impact of C3F8 or SF6 Use and Length of Face-down Positioning (7 vs 14 Days Respectively) in Macular Hole Surgery Completed NCT02073266 Not Applicable
41 Comparison of Small-gauge Vitrectomy and Conventional Vitrectomy for Proliferative Diabetic Retinopathy Completed NCT01758757 Not Applicable
42 Outcomes of Vitrectomy in Pediatric Retinal Detachment With Proliferative Vitreoretinopathy Completed NCT03208205
43 Ultrastructure Analysis of Excised Internal Limiting Membrane in Eyes of Highly Myopia With Myopic Traction Maculopathy Completed NCT02528058
44 27-gauge Vitrectomy Wound Integrity: a Prospective, Randomized Trial Comparing Angled Versus Straight Entry Completed NCT02836210 Not Applicable
45 Ocular Safety Of Patients Receiving Macugen For Neovascular Age Related Macular Degeneration Completed NCT00460408 Macugen
46 Epiretinal Proliferation in Eyes With Full Thickness Macular Hole Completed NCT03376776
47 Outcome of Surgery for Idiopathic Macular Holes Completed NCT02895594
48 Optical Coherence Tomography-based Positioning for Macular Hole Surgery Completed NCT02650739
49 Fundus Autofluorescence After Macular Hole Surgery Completed NCT02628262
50 Unveiling Preclinical Idiopathic Macular Hole Formation Completed NCT02180633

Search NIH Clinical Center for Retinal Perforation

Cochrane evidence based reviews: retinal perforations

Genetic Tests for Retinal Perforation

Anatomical Context for Retinal Perforation

MalaCards organs/tissues related to Retinal Perforation:


Publications for Retinal Perforation

Articles related to Retinal Perforation:

# Title Authors Year
Retinal perforation in strabismus surgery. ( 9083958 )
Choroidal melanoma with retinal perforation and vitreous hemorrhage: a scanning electron microscopic study. ( 6656013 )
Retinal perforation and muscle surgery. ( 5481593 )

Variations for Retinal Perforation

Expression for Retinal Perforation

Search GEO for disease gene expression data for Retinal Perforation.

Pathways for Retinal Perforation

GO Terms for Retinal Perforation

Cellular components related to Retinal Perforation according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 collagen trimer GO:0005581 8.96 COL11A1 COL2A1
2 endoplasmic reticulum lumen GO:0005788 8.8 COL11A1 COL2A1 P3H1

Biological processes related to Retinal Perforation according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 ossification GO:0001503 9.49 COL11A1 COL2A1
2 cartilage development GO:0051216 9.48 COL11A1 COL2A1
3 inner ear morphogenesis GO:0042472 9.46 COL11A1 COL2A1
4 collagen catabolic process GO:0030574 9.43 COL11A1 COL2A1
5 bone development GO:0060348 9.4 COL2A1 P3H1
6 heart morphogenesis GO:0003007 9.37 COL11A1 COL2A1
7 visual perception GO:0007601 9.33 COL11A1 COL2A1 PAX6
8 collagen fibril organization GO:0030199 9.32 COL11A1 COL2A1
9 skeletal system morphogenesis GO:0048705 9.26 COL11A1 COL2A1
10 cartilage condensation GO:0001502 8.96 COL11A1 COL2A1
11 proteoglycan metabolic process GO:0006029 8.62 COL11A1 COL2A1

Molecular functions related to Retinal Perforation according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular matrix structural constituent GO:0005201 8.62 COL11A1 COL2A1

Sources for Retinal Perforation

9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
55 Novoseek
58 OMIM via Orphanet
62 PubMed
70 SNOMED-CT via Orphanet
72 Tocris
74 UMLS via Orphanet
Loading form....